OpGen Inc (OPGN)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:OpGen Inc (OPGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012214
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
OpGen Inc (OpGen) is a molecular diagnostics company that harnesses genomic analysis and bioinformatics to prevent the threat of antibiotic resistance and multi drug resistant organisms (MDROs). The company’s clinical laboratory services include high resolution microbial sequence analysis, swift detection and analysis of antibiotic resistance, and detection of pathogens in blood cultures. It is also developing Acuitas Lighthouse, an exhaustive database of various types of pathogens for providing rapid diagnostics, and healthcare management information. OpGen offers its surveillance products and customized screening services to healthcare providers to protect the hospital biome and optimize patient care. The company sells its products in the US and abroad. OpGen is headquartered in Gaithersburg, Maryland, the US.

OpGen Inc (OPGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
OpGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
OpGen Inc, Medical Devices Deals, 2011 to YTD 2017 10
OpGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
OpGen Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
OpGen Raises USD1.2 Million in Venture Financing 12
Opgen Raises USD1 Million in Venture Financing 13
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 14
OpGen Raises US$2 Million In Venture Financing 15
OpGen Raises Additional US$2.6 Million In Series C Financing 16
OpGen Secures An Additional US$3 Million In Series B Round Of Financing 18
Partnerships 20
OpGen and Hitachi High-Technologies Amends its Agreement to Develop Human Chromosome Mapping Service 20
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 21
OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 22
Life Technologies Enters Into Co-Development Agreement With OpGen 23
OpGen Enters Into Co-Development Agreement With In-Q-Tel 24
Equity Offering 25
OpGen Raises USD0.1 Million in Equity Offering 25
Opgen Raises USD10 Million in Public Offering of Units 26
OpGen Raises USD5 Million in Private Placement of Shares 28
OpGen Raises USD17 Million in IPO 29
Debt Offering 31
OpGen Raises USD0.5 Million in Debt Financing 31
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 32
OpGen Inc – Key Competitors 33
OpGen Inc – Key Employees 34
OpGen Inc – Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 36
Financial Announcements 36
Aug 08, 2017: OpGen Reports 2017 Second Quarter Financial Results and Provides Business Update 36
Apr 26, 2017: OpGen Announces 2017 First Quarter Financial Results 38
Mar 23, 2017: OpGen Announces 2016 Fourth Quarter and Year End Financial Results 39
Jan 26, 2017: OpGen Reports Preliminary Fourth Quarter and Full Year 2016 Financial Results 41
Oct 24, 2016: OpGen Reports 2016 Third Quarter Financial Results and Provides Business Update 43
Aug 09, 2016: OpGen Reports 2016 Second Quarter Financial Results and Provides Business Update 44
May 12, 2016: OpGen Reports 2016 First Quarter Financial Results and Business Update 45
Mar 30, 2016: OpGen Announces 2015 Fourth Quarter and Full Year Financial Results 46
Corporate Communications 47
Apr 27, 2017: OpGen Appoints Tina S. Nova, Ph.D. to Board of Directors 47
May 02, 2016: OpGen Appoints Harry J. D’Andrea to Board of Directors 48
Product News 49
Oct 27, 2016: Large Integrated Health Outcomes Study Reveals Shifting Epidemiology In Drug Resistant Organisms 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
OpGen Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
OpGen Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
OpGen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
OpGen Inc, Deals By Therapy Area, 2011 to YTD 2017 9
OpGen Inc, Medical Devices Deals, 2011 to YTD 2017 10
OpGen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
OpGen Raises USD1.2 Million in Venture Financing 12
Opgen Raises USD1 Million in Venture Financing 13
AdvanDx Raises US$12 Million In Series B-1 Venture Financing 14
OpGen Raises US$2 Million In Venture Financing 15
OpGen Raises Additional US$2.6 Million In Series C Financing 16
OpGen Secures An Additional US$3 Million In Series B Round Of Financing 18
OpGen and Hitachi High-Technologies Amends its Agreement to Develop Human Chromosome Mapping Service 20
OpGen Enters Into Agreement With Applied Maths To Develop Whole Genome Mapping Software 21
OpGen Enters Into Agreement With UC Davis To Develop Microbial Reference Genomes 22
Life Technologies Enters Into Co-Development Agreement With OpGen 23
OpGen Enters Into Co-Development Agreement With In-Q-Tel 24
OpGen Raises USD0.1 Million in Equity Offering 25
Opgen Raises USD10 Million in Public Offering of Units 26
OpGen Raises USD5 Million in Private Placement of Shares 28
OpGen Raises USD17 Million in IPO 29
OpGen Raises USD0.5 Million in Debt Financing 31
OpGen Raises USD1.5 Million in Private Placement of 8% Notes 32
OpGen Inc, Key Competitors 33
OpGen Inc, Key Employees 34
OpGen Inc, Subsidiaries 35

★海外企業調査レポート[OpGen Inc (OPGN)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Neurelis Inc-製薬・医療分野:企業M&A・提携分析
    Summary Neurelis Inc. (Neurelis) is a specialty pharmaceutical company, which develops medicines to target unmet medical need in epilepsy and acute anxiety episodes. The company's product portfolio includes NRL-1 (intranasal diazepam), a proprietary formulation, for epilepsy in pediatric and adult p …
  • SJVN Ltd (SJVN):企業の財務・戦略的SWOT分析
    SJVN Ltd (SJVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Trustpower Limited (TPW):企業の財務・戦略的SWOT分析
    Trustpower Limited (TPW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Dino Polska S.A (DNP):企業の財務・戦略的SWOT分析
    Dino Polska S.A (DNP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Luye Pharma Group Ltd (2186):製薬・医療:M&Aディール及び事業提携情報
    Summary Luye Pharma Group Ltd (Luye Pharma Group) is a drug company that manufactures, develops, discovers, and commercializes novel formulations, natural drugs, medicinal products, pharmaceutical products, and biotechnology products. The group’s products include paclitaxel liposome, lentinan, sodiu …
  • Probiogen AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Probiogen AG (Probiogen) a subsidiary of Minapharm Pharmaceuticals & Chemical Industries is a contract development and manufacturing organization that offers cell line engineering, process development and GMP manufacturing of biopharmaceuticals. The organization’s services comprise therapeut …
  • Arup Group Ltd:企業の戦略的SWOT分析
    Arup Group Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • ESAB Holdings Ltd:企業の戦略・SWOT・財務情報
    ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary ESAB Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Blue Apron Inc. (APRN):企業の財務・戦略的SWOT分析
    Blue Apron Inc. (APRN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Bank of Ireland:戦略・SWOT・企業財務分析
    Bank of Ireland - Strategy, SWOT and Corporate Finance Report Summary Bank of Ireland - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Urstadt Biddle Properties Inc:企業の戦略・SWOT・財務分析
    Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report Summary Urstadt Biddle Properties Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Parity Group plc (PTY):企業の財務・戦略的SWOT分析
    Summary Parity Group plc (Parity) is a technology company that offers professional recruitment, IT solutions and consultancy services. The company’s technology solutions include business intelligence, database analytics and development; IT consulting and application management support.The company pr …
  • University of York-製薬・医療分野:企業M&A・提携分析
    Summary University of York (York) is an educational and research university that offers academic research and teaching services. The university offers commercial facilities and services, funding collaborative research, knowledge transfer partnerships, professional development and training, consultan …
  • Flowonix Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Flowonix Medical Inc (Flowonix), formerly Medasys Inc is a medical device company that designs and manufactures implantable drug pump to deliver therapeutic drugs into the spine to relieve chronic disorders. The company's products include prometra pump, catheter, and accessories and programm …
  • iNova Pharmaceuticals (Australia) Pty Ltd:企業の戦略的SWOT分析
    iNova Pharmaceuticals (Australia) Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • GAMCO Investors, Inc.:企業の戦略・SWOT・財務情報
    GAMCO Investors, Inc. - Strategy, SWOT and Corporate Finance Report Summary GAMCO Investors, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Zydus Wellness Ltd (ZYDUSWELL):企業の財務・戦略的SWOT分析
    Zydus Wellness Ltd (ZYDUSWELL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • LuLu Group International:企業の戦略・SWOT・財務情報
    LuLu Group International - Strategy, SWOT and Corporate Finance Report Summary LuLu Group International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Anteo Diagnostics Ltd (ADO):企業の製品パイプライン分析2018
    Summary Anteo Diagnostics Ltd (Anteo Diagnostics) is a leading medical technology company that develops and commercializes healthcare products. The company along with its subsidiaries provides immunoassays, in-vitro diagnostics, and point of care (PoC) tests to life sciences, bio-separation, clinica …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆